Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 extension trial in moderate to severe chronic plaque psoriasis
2009-017234-51Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in plaque psoriasis, sponsored by Novartis. Primary endpoint: Long-term safety and tolerability. Started Mar 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2009-017234-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017234-51.